STOCK TITAN

Vanguard (NYSE) reports 0 shares in Syndax after realignment (SNDX)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Syndax Pharmaceuticals Inc Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 causing certain Vanguard subsidiaries to report holdings separately.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings and reports no beneficial ownership in Syndax.

The filing states 0 shares and 0% beneficial ownership as reported by The Vanguard Group following an internal realignment. The disclosure cites January 12, 2026 and SEC Release No. 34-39538 for the change in reporting treatment.

Cash-flow treatment and any subsidiary holdings are not provided in this excerpt; subsequent filings by Vanguard subsidiaries may list holdings separately.






87164F105

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026
Syndax Pharmaceuticals Inc

NASDAQ:SNDX

View SNDX Stock Overview

SNDX Rankings

SNDX Latest News

SNDX Latest SEC Filings

SNDX Stock Data

2.18B
86.32M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK